European Union - English - EMA (European Medicines Agency)

abbvie ltd - venetoclax - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents - venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (cll) in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor.

Canada - English - Health Canada

abbvie corporation - venetoclax - tablet - 10mg - venetoclax 10mg - antineoplastic agents

Canada - English - Health Canada

abbvie corporation - venetoclax - tablet - 50mg - venetoclax 50mg - antineoplastic agents

Canada - English - Health Canada

abbvie corporation - venetoclax - tablet - 100mg - venetoclax 100mg - antineoplastic agents

Canada - English - Health Canada

abbvie corporation - venetoclax; venetoclax; venetoclax - kit - 10mg; 50mg; 100mg - venetoclax 10mg; venetoclax 50mg; venetoclax 100mg - antineoplastic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - venetoclax - tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - venetoclax - tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - venetoclax - tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - ixazomib citrate - capsule - 3mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - ixazomib citrate - capsule - 2.3mg